- Delivering Pan India
Nublexa® (Regorafenib) Regorafenib 40 mg film-coated tablets by Bayer. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Regorafenib 40 mg |
|---|---|
| Manufacturer | Bayer |
| Country | Germany |
| Pack size | Regorafenib 40 mg: 28 tablets |
| Storage | As per carton and leaflet; original pack |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Nublexa® (Regorafenib) Regorafenib 40 mg Film-Coated Tablets — Oral Multikinase Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Nublexa® is a brand of regorafenib 40 mg film-coated tablets, an oral kinase inhibitor. According to the US prescribing information for the reference product (Stivarga®), regorafenib is indicated for adult patients with previously treated metastatic colorectal cancer, previously treated gastrointestinal stromal tumor and previously treated hepatocellular carcinoma. The brand is listed under Bayer, the originator of regorafenib. Indications for Nublexa in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe regorafenib, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Nublexa® (regorafenib) Regorafenib 40 mg film-coated tablets to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Nublexa contains regorafenib 40 mg per film-coated tablet. The Nublexa carton states 28 film-coated tablets per pack, for oral use.
How it works, according to the label: The reference label describes regorafenib as a kinase inhibitor, and notes it is metabolised by CYP3A4 and UGT1A9.
The current US prescribing information for Stivarga® (regorafenib tablets) (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Nublexa pack insert.
The Stivarga label summarises three pivotal studies: CORRECT (metastatic colorectal cancer), GRID (gastrointestinal stromal tumor) and RESORCE (hepatocellular carcinoma). The CORRECT trial was published by Grothey et al. in The Lancet in 2013. Full results are in the DailyMed prescribing information. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Regorafenib 40 mg | Film-coated tablets (oral) | 28 tablets |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, gastrointestinal and hepatobiliary oncology department buyers, and pharmacies that source oral oncology products. Regorafenib is prescribed and supervised by a physician, as described in the prescribing information.
The Stivarga label lists, among adverse reactions occurring in 20% or more of patients, pain, hand-foot skin reaction, asthenia or fatigue, diarrhea, decreased appetite, hypertension, infection, dysphonia, hyperbilirubinemia, fever, mucositis, weight loss, rash and nausea. It carries a boxed warning for severe and sometimes fatal hepatotoxicity. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Nublexa carton and leaflet. For reference, the US Stivarga label describes storage at 25°C in the original bottle with the desiccant, bottle tightly closed. Keep out of reach of children.
Nublexa is marketed by Bayer. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Nublexa through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Nublexa available in India?
A.K. Pharma supplies Nublexa (regorafenib) Regorafenib 40 mg film-coated tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Nublexa contain?
Regorafenib 40 mg per film-coated tablet, an oral kinase inhibitor, in a pack of 28 tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Nublexa be stored?
As printed on the carton and leaflet. The US Stivarga label describes storage at 25°C in the original bottle.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
